External

iPSC Seminars: Early Drug Discovery Unit (EDDU)

admin — Thu, 31 Jul 2025 15:32:34 +0000

THE NEURO'S EDDU iPSC SEMINAR SERIES

Modeling α-Synuclein Pathology Spreading in a 3D Human Midbrain-Striatal Assembloid

8th National Neuromuscular Review Course

admin — Thu, 13 Feb 2025 16:08:29 +0000

Dr. Nicolas Dupré of Laval University, Dr. Karine Garneau of Université de Montréal, and the members of the organizing committee are pleased to announce the 8th National Neuromuscular Review Course.

Hughlings Jackson Lecture 2025: The Basal Ganglia and the Motivation to Act

admin — Mon, 13 Jan 2025 21:40:52 +0000

Established in 1935, the Hughlings Jackson Lecture is The Neuro’s premier scientific lecture. It honours the legacy of British neurologist John Hughlings Jackson (1835-1911) who pioneered the development of neurology as a medical specialty.

6th National Course on Sleep Medicine

admin — Thu, 12 Dec 2024 14:46:27 +0000

This two-day training course is designed to provide and enhance a basic working knowledge of sleep medicine.

Neuro Epilepsy Lecture Series: AI in Epilepsy: From Diagnosis to Continuous Monitoring

admin — Tue, 05 Aug 2025 17:49:37 +0000

The 2024-2025 Neuro Epilepsy Lecture Series will include eight lectures covering hot topics in basic and clinical epilepsy research.

Pearl Eliadis Contributes to Canada’s National Consultation for X Summit of the Americas

admin — Thu, 14 Aug 2025 17:02:05 +0000

August 14, 2025 | 91��, in partnership with the Organization of American States (OAS), hosted Canada’s National Consultation for the upcoming X Summit of the Americas. Pearl Eliadis was among the contributors recognized for advancing an inter-American conversation rooted in openness, purpose, and collective action. The event, organized through the 91�� School of Continuing Studies, brought together voices from civil society, academia, government, and communities.

Experts: back-to-school

aurelie.boucher@mcgill.ca — Wed, 13 Aug 2025 19:32:39 +0000

With the first day of school fast approaching, 91�� experts are available to comment on a variety of related issues.

Mental health and well-being

Marie-Claude Geoffroy, Associate Professor, Department of Psychiatry and Douglas Mental Health University Institute, is the Canada Research Chair in Youth Suicide Prevention. She can discuss youth mental health.

marie-claude.geoffroy [at] mcgill.ca (English, French)

91�� team discovers Canada’s first dinosaur-era dragonfly fossil

claire.loewen@mcgill.ca — Wed, 13 Aug 2025 17:08:07 +0000

In a first for Canadian paleontology, a Cretaceous fossilized dragonfly wing, uncovered in Alberta’s Dinosaur Provincial Park, has been identified as a new species. It’s also the first known dragonfly fossil from Canada’s dinosaur aged rocks. The find, led by 91�� researchers, sheds light on a 30-million-year gap in the evolutionary history of dragonflies.

The fossil was discovered in 2023 by a 91�� undergraduate student during a vertebrate paleontology field course led by Prof. Hans Larsson.

Latest Alzheimer’s drug shown less effective in females than males

admin — Tue, 18 Mar 2025 18:27:46 +0000

Since becoming only the second Alzheimer’s-modifying drug to gain American FDA approval in 2023, sales of lecanemab, known by its brand name Leqembi, have risen steadily, reaching $87-million USD in the last quarter of 2024.

Genetic sequencing project receives more than $8 million in funding

admin — Tue, 18 Mar 2025 14:55:14 +0000

NeuRo Genomics Initiative will help better understand rare and aging-related neurological disorders affecting Canadians

A project led by Ziv Gan-Or, MD, PhD, at The Neuro (Montreal Neurological Institute-Hospital) of 91�� and Martine Tétreault, PhD, at Université de Montréal has received more than $8 million to sequence the genomes of 8,700 people, to map the role of genetics in neurological disorders.

Project to create AI model for ALS receives Génome Québec funding

admin — Mon, 17 Mar 2025 15:29:17 +0000

$400,000 will fuel public-private collaboration to discover new disease biomarkers

A new project co-led by Thomas Durcan, PhD, Director of The Neuro's Early Drug Discovery Unit, and overseen by Mathilde Chaineau, PhD, the EDDU’s program manager, will receive $400,000 in support from Génome Québec. In partnership with Nardin Nakhla and Armstrong Murira from the Montreal-based company Simmunome, Durcan and Chaineau will develop a computational model of amyotrophic lateral sclerosis (ALS) on which to test for new biomarkers and therapeutic targets.

Human instruction with artificial intelligence guidance provided best results in neurosurgical training

admin — Wed, 06 Aug 2025 15:14:02 +0000

Study has implications beyond medical education, suggesting other fields could benefit from AI-enhanced training

Artificial intelligence (AI) is becoming a powerful new tool in training and education, including in the field of neurosurgery. Yet a new study suggests that AI tutoring provides better results when paired with human instruction.

Achievements of clinicians and scientists recognized with King Charles III Coronation Medals

admin — Fri, 14 Mar 2025 13:09:39 +0000

Five clinicians and scientists at The Neuro have been awarded King Charles III Coronation Medals in recognition of their contributions to our understanding of neurological disease. The Coronation Medal commemorates the Coronation of His Majesty King Charles III as King of Canada. The medal is administered by the Chancellery of Honours at Rideau Hall.

AI analysis of healthcare records reveals key factors in autism diagnosis

admin — Wed, 26 Mar 2025 15:23:21 +0000

Scientists argue the criteria we use for diagnosing autism may need revision

Without clear and effective biological tests for autism based on genes, brain or blood measurements, diagnosis today still largely depends on clinical assessment. The standard way of doing this is by observing how the individual fits the criteria for autism listed in gold standard manuals like the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5).

Prescribing anti-swelling drug reduces immune response weeks after last dose

admin — Wed, 26 Feb 2025 16:05:58 +0000

Mapping immune cell diversity reveals dexamethasone’s impact on brain cancer immunotherapy

Swelling caused by brain cancer is a problem that can lead to serious side effects and even death. While controlling swelling is important, a new study shows that a commonly prescribed anti-swelling drug suppresses the immune system for weeks after dosage, inhibiting the body’s ability to fight the cancer.